BREA, Calif., May 18, 2020 /PRNewswire/ -- Beckman Coulter
announced today the availability of its DxH 690T hematology
analyzer in the U.S. Designed to streamline workflow and
minimize downtime in mid-volume laboratories, the DxH 690T delivers
all of the benefits of the company's flagship DxH 900 large-volume
hematology analyzer in a table-top configuration.
Hematology analysis is a critical part of triaging patients in
urgent care settings. The DxH 690T brings mid-volume laboratories
advanced features such as the Early Sepsis Indicator (ESId)
available on Beckman Coulter's larger high-volume analyzer, the
DxH900. ESId is a novel FDA-cleared, hematology-based cellular
biomarker included as part of a standard CBC
with differential, which is designed to help emergency
department physicians identify adult patients with sepsis or at
increased risk of developing sepsis.
"Managing increased demand for testing, while maximizing
resource efficiency is top of mind for laboratorians even in the
best of circumstances," said Peter
Soltani, Ph.D., senior vice president and general manager of
the hematology business unit at Beckman Coulter. "For
mid-volume labs, this is no exception. The DxH 690T reports high
confidence results and improves turnaround time by reducing
procedural steps and manual touchpoints, making it an ideal
solution to help relieve some of this burden. The DxH 690T also
supports standardization across hospital networks to a single
platform—DxH 900 for larger-volume labs and DxH 690T for
mid-volume."
The DxH 690T applies Beckman Coulter's core hematology
technologies—the enhanced Coulter Principle, VCS 360 and
DataFusion—to streamline throughput, minimize reflex testing and
reduce manual interventions. Utilizing these technologies for
high-resolution analysis of cells in their near native-states, the
DxH 690T ensures mid-volume laboratories can achieve the right
results the first time without unnecessary reflex or repeats.
Commercially available worldwide today, the DxH 690T builds on
Beckman Coulter's strength and history in hematology innovation and
complements its broad hematology portfolio, including the DxH 520
for low-volume, the DxH 900 for high-volume and the DxH connected
workcell solutions for ultra-high-volume facilities.
For more information on the DxH 690T or Beckman Coulter's full
portfolio of hematology solutions, visit
www.BeckmanCoulter.com/DxH690T.
About Beckman Coulter
Beckman Coulter is committed to
advancing healthcare for every person by applying the power of
science, technology and the passion and creativity of our teams to
enhance the diagnostic laboratory's role in improving healthcare
outcomes. Our diagnostic systems are used in complex biomedical
testing, and are found in hospitals, reference laboratories and
physician office settings around the globe. Beckman Coulter offers
a unique combination of people, processes and solutions designed to
elevate the performance of clinical laboratories and healthcare
networks. We do this by accelerating care with a menu that matters,
bringing the benefit of automation to all, delivering greater
insights through clinical informatics and unlocking hidden value
through performance partnership. An operating company of Danaher
Corporation (NYSE: DHR) since 2011, Beckman Coulter is
headquartered in Brea, Calif., and
has more than 11,000 global associates working diligently to make
the world a healthier place.
© 2020 Beckman Coulter. All rights reserved. Beckman Coulter,
the stylized logo, and the Beckman Coulter product and service
marks mentioned herein are trademarks or registered trademarks of
Beckman Coulter, Inc. in the United
States and other countries.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/beckman-coulter-launches-dxh-690t-mid-volume-hematology-analyzer-featuring-the-early-sepsis-indicator-in-us-market-301060924.html
SOURCE Beckman Coulter Diagnostics